COPD clinical trials in Gary, IN
3 studies for COPD are looking for participants at sites in and around Gary (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
RecruitingPhase 3
- Velocity Clinical Research ( Site 4464), Valparaiso · 17 mi away
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
RecruitingPhase 2/3
- Methodist Hospital Southlake, Merrillville · 8 mi away
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
- Research Site, Valparaiso · 17 mi away
About COPD
COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. At first symptoms are mild, but they usually become more severe. Learn more.
More about COPD on MedlinePlus
COPD trials in other cities
- Philadelphia, PA26 studies
- Miami, FL20 studies
- Houston, TX18 studies
- Birmingham, AL17 studies
- Baltimore, MD16 studies
- Boston, MA15 studies
- Orlando, FL15 studies
- Chicago, IL15 studies
- Dallas, TX13 studies
- New York City, NY12 studies
- Pittsburgh, PA11 studies
- Winston-Salem, NC11 studies
Other studies in Gary
- Non-Small Cell Lung Cancer7 studies
- Lung Cancer7 studies
- Acute Myeloid Leukemia5 studies
- Heart Failure5 studies
- Ovarian Cancer4 studies
- Breast Cancer4 studies
- Atrial Fibrillation4 studies
- Blood Clots3 studies
- Esophageal Adenocarcinoma3 studies
- Endometrial Cancer3 studies
- Head and Neck Squamous Cell Carcinoma3 studies
- Bladder Cancer3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.